

**NEWMARKET CORPORATION AND SUBSIDIARIES**  
**SEGMENT RESULTS AND OTHER FINANCIAL INFORMATION**  
(In millions except per share amounts, unaudited)

	Three Months Ended September 30		Nine Months Ended September 30	
	2007	2006	2007	2006
<b>Net sales:</b>				
Petroleum additives	\$ 352.5	\$ 323.9	\$ 998.6	\$ 948.4
All other (a)	4.4	1.2	12.2	8.7
<b>Total</b>	<b>\$ 356.9</b>	<b>\$ 325.1</b>	<b>\$ 1,010.8</b>	<b>\$ 957.1</b>
<b>Segment operating profit:</b>				
Petroleum additives before special item	\$ 35.2	\$ 27.8	\$ 100.7	\$ 80.6
Special item (b)	-	2.6	-	2.6
<b>Petroleum additives</b>	<b>35.2</b>	<b>30.4</b>	<b>100.7</b>	<b>83.2</b>
<b>All other (a)</b>	<b>0.6</b>	<b>(2.3)</b>	<b>(4.4)</b>	<b>(0.7)</b>
<b>Segment operating profit</b>	<b>35.8</b>	<b>28.1</b>	<b>96.3</b>	<b>82.5</b>
Corporate unallocated expense	(3.0)	(3.9)	(10.2)	(9.8)
Special items (c)	-	5.3	-	13.0
Interest expense	(3.0)	(3.9)	(8.7)	(11.7)
Other income, net	1.4	1.0	2.4	2.3
<b>Income from continuing operations before income taxes</b>	<b>\$ 31.2</b>	<b>\$ 26.6</b>	<b>\$ 79.8</b>	<b>\$ 76.3</b>
<b>Net income:</b>				
Income from continuing operations excluding special items	\$ 20.1	\$ 11.9	\$ 51.5	\$ 39.2
Special items (b) (c)	-	4.9	-	9.8
Discontinued operations (d)	1.1	2.1	16.8	4.1
<b>Net income</b>	<b>\$ 21.2</b>	<b>\$ 18.9</b>	<b>\$ 68.3</b>	<b>\$ 53.1</b>
<b>Basic earnings per share:</b>				
Earnings excluding discontinued operations and special items	\$ 1.20	\$ 0.70	\$ 3.01	\$ 2.27
Special items (b) (c)	-	0.28	-	0.57
Discontinued operations (d)	0.06	0.12	0.98	0.24
<b>Basic earnings per share</b>	<b>\$ 1.26</b>	<b>\$ 1.10</b>	<b>\$ 3.99</b>	<b>\$ 3.08</b>
<b>Diluted earnings per share:</b>				
Income from continuing operations excluding special items	\$ 1.19	\$ 0.69	\$ 2.99	\$ 2.25
Special items (b) (c)	-	0.28	-	0.56
Discontinued operations (d)	0.06	0.12	0.97	0.24
<b>Diluted earnings per share</b>	<b>\$ 1.25</b>	<b>\$ 1.09</b>	<b>\$ 3.96</b>	<b>\$ 3.05</b>

**Notes to Segment Results and Other Financial Information**

- (a) During the second quarter 2007 and after the settlement of the Arbitration Actions with Innospec Inc. (Arbitration Actions) and the resulting termination of the tetraethyl lead (TEL) marketing agreements with Innospec Inc. (see note d), we determined the continuing operations of our TEL business no longer represented a significant segment. As a result, we have reclassified the continuing results of our TEL business in the "All other" caption above. Also included in the "All other" caption is certain contract manufacturing of Ethyl Corporation. Prior periods have been reclassified.
- (b) The 2006 special item in petroleum additives represents the gain associated with a legal settlement related to transportation charges. The after tax gain amounted to \$1.6 million.
- (c) Both third quarter and nine months 2006 include a \$5.3 million gain (\$3.3 million after tax) related to an earn-out agreement for certain pharmaceutical intellectual property that we sold in 1994. Nine months 2006 also includes a \$4.4 million gain (\$2.9 million after tax) for interest on an income tax settlement, as well as a \$3.3 million gain (\$2.0 million after tax) on the sale of property.
- (d) Discontinued operations reflect the settlement of the Arbitration Actions and the resulting termination of the TEL marketing agreements with Innospec Inc. effective April 1, 2007. The gain on the settlement of this business was \$22.8 million (\$14.6 million after tax or \$.84 per share) for nine months 2007 including a \$1.7 million (\$1.1 million after tax or \$.06 per share) benefit in the third quarter 2007. The remaining amounts for the 2007 and 2006 periods represent the after tax earnings of the discontinued business.

**NEWMARKET CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF INCOME**  
(In thousands except per share amounts, unaudited)

	Three Months Ended September 30		Nine Months Ended September 30	
	2007	2006	2007	2006
<b>Net sales</b>	<b>\$ 356,946</b>	<b>\$ 325,119</b>	<b>\$ 1,010,755</b>	<b>\$ 957,135</b>
Cost of goods sold	277,877	258,955	786,739	757,266
<b>Gross profit</b>	<b>79,069</b>	<b>66,164</b>	<b>224,016</b>	<b>199,869</b>
Selling, general, and administrative expenses	27,659	27,794	81,460	79,260
Research, development, and testing expenses	18,476	16,582	56,387	50,264
Special items income (a)	-	7,843	-	11,093
<b>Operating profit</b>	<b>32,934</b>	<b>29,631</b>	<b>86,169</b>	<b>81,438</b>
Interest and financing expenses	2,954	3,917	8,743	11,689
Other income, net (b)	1,235	859	2,382	6,502
<b>Income from continuing operations before income taxes</b>	<b>31,215</b>	<b>26,573</b>	<b>79,808</b>	<b>76,251</b>
Income tax expense	11,125	9,715	28,254	27,282
<b>Income from continuing operations</b>	<b>20,090</b>	<b>16,858</b>	<b>51,554</b>	<b>48,969</b>
Discontinued operations (c):				
Gain on settlement of discontinued business (net of tax)	1,067	-	14,554	-
Income from operations of discontinued business (net of tax)	-	2,063	2,217	4,093
<b>Net income</b>	<b>\$ 21,157</b>	<b>\$ 18,921</b>	<b>\$ 68,325</b>	<b>\$ 53,062</b>
<b>Basic earnings per share</b>				
Income from continuing operations	\$ 1.20	\$ 0.98	\$ 3.01	\$ 2.84
Discontinued operations (c)	0.06	0.12	0.98	0.24
	<b>\$ 1.26</b>	<b>\$ 1.10</b>	<b>\$ 3.99</b>	<b>\$ 3.08</b>
<b>Diluted earnings per share</b>				
Income from continuing operations	\$ 1.19	\$ 0.97	\$ 2.99	\$ 2.81
Discontinued operations (c)	0.06	0.12	0.97	0.24
	<b>\$ 1.25</b>	<b>\$ 1.09</b>	<b>\$ 3.96</b>	<b>\$ 3.05</b>
<b>Shares used to compute basic earnings per share</b>	<b>16,772</b>	<b>17,257</b>	<b>17,121</b>	<b>17,204</b>
<b>Shares used to compute diluted earnings per share</b>	<b>16,887</b>	<b>17,409</b>	<b>17,236</b>	<b>17,405</b>
<b>Cash dividends declared per share</b>	<b>\$ 0.125</b>	<b>\$ 0.125</b>	<b>\$ 0.375</b>	<b>\$ 0.375</b>

**Notes to Consolidated Statements of Income**

- (a) Both third quarter and nine months 2006 include a \$5.3 million gain (\$3.3 million after tax) related to an earn-out agreement for certain pharmaceutical intellectual property that we sold in 1994. In addition, both 2006 periods also include a gain of \$2.6 million (\$1.6 million after tax) associated with a legal settlement related to transportation charges. Nine months 2006 also includes a \$3.3 million gain (\$2.0 million after tax) on the sale of property.
- (b) Other income, net for nine months 2006 includes a gain of \$4.4 million for interest on an income tax settlement. The after tax gain amounted to \$2.9 million.
- (c) Discontinued operations reflect the settlement of the Arbitration Actions and the resulting termination of the TEL marketing agreements with Innospec Inc. effective April 1, 2007. The gain on the settlement of this business was \$22.8 million (\$14.6 million after tax or \$.84 per share) for nine months 2007 including a \$1.7 million (\$1.1 million after tax or \$.06 per share) in the third quarter 2007. The income from operations for the 2007 and 2006 periods represent the after tax earnings of the discontinued operations. Income from operations before tax amounted to \$3.5 million for nine months 2007, \$3.2 million for the third quarter 2006, and \$6.4 million for nine months 2006.

**NEWMARKET CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**

(In thousands)

	September 30 2007 (unaudited)	December 31 2006
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 82,947	\$ 60,300
Restricted cash	210	240
Trade and other accounts receivable, less allowance for doubtful accounts (\$880 - 2007; \$835 - 2006)	212,490	198,243
Inventories	191,833	185,581
Deferred income taxes	18,290	12,277
Prepaid expenses	5,455	5,319
<b>Total current assets</b>	<b>511,225</b>	<b>461,960</b>
Property, plant and equipment, at cost	779,814	751,355
Less accumulated depreciation and amortization	600,345	589,241
<b>Net property, plant and equipment</b>	<b>179,469</b>	<b>162,114</b>
Prepaid pension cost	1,298	85
Deferred income taxes	16,599	30,088
Other assets and deferred charges	22,085	38,838
Intangibles, net of amortization	47,093	51,708
<b>Total assets</b>	<b>\$ 777,769</b>	<b>\$ 744,793</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 96,948	\$ 81,623
Accrued expenses	55,264	59,692
Dividends payable	2,023	2,162
Book overdraft	3,525	2,549
Long-term debt, current portion	724	691
Income taxes payable	14,931	13,466
<b>Total current liabilities</b>	<b>173,415</b>	<b>160,183</b>
Long-term debt	156,886	152,748
Other noncurrent liabilities	127,124	130,460
Shareholders' equity		
Common stock and paid in capital (without par value) Issued - 16,180,821 in 2007 and 17,289,860 in 2006	38,389	88,263
Accumulated other comprehensive loss	(40,328)	(47,165)
Retained earnings	322,283	260,304
<b>Total liabilities and shareholders' equity</b>	<b>\$ 777,769</b>	<b>\$ 744,793</b>